History & Evolving Role of Interferon in Myeloproliferative Neoplasms | Supplements And Featured Publications

Dr. Kambhampati on Interferon and Novel Agents in MPNs

March 12, 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.

Dr. Kiladjian on the RUXOPeg Trial in Myelofibrosis

March 12, 2019

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses the RUXOPeg trial in myelofibrosis.

Dr. Kiladjian on Ruxolitinib Plus Interferon in MPNs

February 27, 2019

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses a study of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasms.

Dr. Kambhampati Discusses Role of Interferon in MPNs

February 26, 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.